ITOG Chair Quarterly Update
January 2019
Greetings ITOG Members and Friends!

Manisha Shah, MD
ITOG Chair

It has been such an honor being elected and serving as the ITOG Chair. The Executive Committee, Board of Directors, and ITOG Committees have been very busy since the 2018 Annual Meeting addressing the top priority projects our membership has identified. This includes Membership Expansion, an ITOG Registry, updating the ITOG Website, organizational collaborations, relocating the 2019 Annual Meeting, and EORTC discussions.

www.ITOG.org

ITOG Active Clinical Trials

ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radiodine-resistant Differentiated Thyroid Cancers
Accrual Status: Accruing
Accrual Goal: 60
Current Accrual: 28
Principal Investigator: Bryan Haugen, MD
Principal Investigator Email: Bryan.Haugen@ucdenver.edu
University of Colorado Medical Center
Protocol Contact: Bridget Schweitzer
Email: mailto:elsing.alicia@mayo.edu

Selumetinib plus Rai for RAI-Avid Thyroid Cancers
Accrual Status: Accruing
Accrual Goal: 60
Current Accrual: 48
Principal Investigator: Alan Ho MD, PhD,
Principal Investigator Email: hoa@mskcc.org
Memorial Sloan-Kettering Cancer Center
Protocol Contact: Bridget Schweitzer
Email: elsing.alicia@mayo.edu

Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Accrual Status: Permanently closed to Accrual
Accrual Goal: 25
Current Accrual: 25
Principal Investigator: Manisha Shah, MD
Principal Investigator Email: manisha.shah@osumc.edu
The Ohio State University
Protocol Contact: Stephanie Noble Email: noble.stephanie@mayo.edu
Accrual objective met; permanently closed to patient accrual effective February 19, 2016. All patients off study. Clinical result. Correlative Studies Analysis is ongoing. Manuscript published: Cabozantinib as Salvage Therapy for Patients with Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial (DOI: 10.1200/JCO.2017.73.0226 Journal of Clinical Oncology - published online before print August 17, 2017. PMID: 28817373. Published in print October 2017; official reference citation is J Clin Oncol 2017;

www.ITOG.org

2019 ITOG Annual Meeting, New York, NY
May 3, 2019  5:00 PM - May 5, 2019  12:00 Noon
Zuckerman Auditorium, Memorial Sloan Kettering Cancer Center, New York, NY
Hosts: Dr. David Pfister, Dr. Eric Sherman, Dr. Alan Ho, Dr. Michael Tuttle and Team

ITOG Latest News!

ITOG Membership Vote to Approve ITOG/REACT Merger - This merger ..... for more information about the Michelle LeBeau and the REACT Foundation Click Here.

First ITOG Trial/NCI 9312/Cabo in DTC - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy

New Trial...Cabo/Nivo/Ipi s/p VEGF-targeted therapies

ITOG Thyroid Cancer Registry

Call for 2020 Annual Meeting Host Now Open - International Members Encouraged

Welcome New Members!

Dora Dias-Santagata, PhD, FACMG,
(Pathologist)
Massachusetts General Hospital
Call for ITOG Committee Volunteers

Committee Terms May 2019 – April 2022

ITOG committee members must be a member of ITOG in good standing. Committee members have the overall responsibility for supporting the ITOG Board of Directors and carrying out the committee charges as set forth by the Board of Directors.

We are currently seeking volunteers for the following committees:

- Basic Science and Correlative Science
- Clinical Protocols
- Finance
- Website and Communications
- By-Laws
- Development
- Membership

Click Here To Volunteer

ITOG Members Presentations

September - December 2018

(To submit your presentations for next issue - Click here)

EORTC Endocrine Tumor Group Meeting  November 22, 2018  Milan, Italy

- Moderators: Jaume Capdevila; Ettore Seregni - Design an algorithm for treatment of advanced thyroid cancer
- Sophie Leboulleux, MD - Focus on redifferentiation strategies
- Manisha Shah, MD - MTC: what can we expect with anti Ret drugs?
- Sebastiano Filetti, MD - Update on ESMO guidelines 2018

ESMO Congress
October 19- 23 Munich Germany

- Jaume Capdevila Castillon, MD - Efficacy of Lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
- Sophie Leboulleux, MD - (1) Novel targeted therapies in thyroid carcinoma (2) Tumor Growth Rate and Lenvatinib Efficacy in Radioiodine-refractory Differentiated Thyroid Cancer
- Christine Spitzweg, MD

18th Congress of the European NeuroEndocrine Association
October 17 - 20, 2018 Wrocław, Poland

- Manisha Shah, MD - Targeted therapies in MTC

21st International Thyroid Cancer Survivors' Conference (ThyCa)
October 19 - 21, 2018 Oaklawn, Ill
• Marcia S. Brose, M.D., Ph.D., (1) You are radioactive iodine (RAI) refractory: Now what? (2) How to determine whether a clinical trial is your best option, and how to identify a suitable trial. (2) Papillary and follicular thyroid cancer standard of care and toxicity management.

• Naifa L. Busaidy, M.D., - Papillary and follicular thyroid cancer: After diagnosis, when and how to treat, OR when “active surveillance” or “watch and wait” is an option.

• Maria E. Cabanillas, M.D. - (1) Novel chemotherapies for patients with metastatic papillary, follicular, or Hurthle cell thyroid cancer. (2) Anaplastic thyroid cancer: Changes in treatment and new approaches that show promise.

• Gilbert J. Cote, Ph.D., - (1) Understanding the biology of medullary thyroid cancer. (2) Molecular markers in medullary thyroid cancer, and what they mean for future treatment advances.

• Robert F. Gagel, M.D.- (1) Medullary thyroid cancer: An overview of important treatment. (2) The realities of getting a drug approved by the FDA, and how the FDA views medullary thyroid cancer

• Bhavana Konda, M.D., M.PH.- Systemic treatment options for radioactive iodine-refractory metastatic papillary, follicular, and Hurthle cell thyroid cancer.

• Yuri Nikiforov, M.D., Ph.D., - Molecular diagnostics and prognostication in all types of thyroid cancer: What the latest research tells us.

• S. Michael Rothenberg, M.D., Ph.D., - From multi-kinase inhibitors (MKIs) to targeted tyrosine kinase inhibitors (TKIs): Designing therapies for thyroid cancer patients to maximize responses and minimize side effects.

• R. Michael Tuttle, M.D., - (1) The ABCs of thyroid cancer: Explaining key terms, concepts, and initial diagnostic and treatment steps. (2) Medullary thyroid cancer: Update on medical management.

• Lori J. Wirth, M.D., - An update on medullary thyroid cancer therapy drugs, both FDA approved and in clinical trial.

---

**ITOG Member Publications**

(To submit your publications for next issue - [Click here])

**Primary Adrenal Insufficiency during Lenvatinib or Vandetanib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.** Colombo C, De Leo S, Di Stefano M, Vannucchi G, Persani L., Fugazzola L

---

**Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radiiodine-refractory differentiated thyroid cancer.**

Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A.

---

**ITOG Upcoming Meetings**

**ITOG General Membership Calls**

Thursdays 11:00AM (EST)

- January 24

**ITOG Executive Committee Calls**

Wednesdays 4:30PM (EST)

- January 9
May 23

ITOG Board of Director Calls
Mondays 6:00PM (EST)

- February 25
- April 22
- June 24
- July 29

January 23
January 30
February 13
February 27
March 27
April 10
April 24
May 8
May 22

---

2019 Industry Meetings and Events

AACE/ACE Clinical Symposium  February 2-3,  Tampa, FL
A4M/MMI  Clinical Endocrinology Symposium  March 7 -9, Houston, TX
AACR Annual Meeting 2019  March 29 – April 3,  Atlanta, GA
AACE April 24-28,  Los Angeles, CA
ITOG Annual Meeting May 3-5,  New York, NY
Alliance 2019 Spring Group Meeting May 9 – 11, 2019  Rosemont, IL
BIT’s 12th Annual World Cancer Congress 2019  May 15-17,  Osaka, Japan
ASCO 2019  May 21 – June 4, Chicago, IL
World Congress on Thyroid Cancer 3.5,  June 20 – 22,  Rome, Italy
NANETS Annual Symposium  October 3-5,  Boston, MA
ThyCa 22nd International Conference  October 18 – 20,  Denver, CO
ATA 89th Annual Meeting  October 30-November 3,  Chicago, IL
Alliance 2019 Fall Group Meeting  November 7 – 9,  Rosemont, IL
42nd Annual Meeting of the European Thyroid Association  September 7 – 10  Budapest, Hungary
Development

Donations to ITOG support our mission to catalyze a cure for thyroid cancer. Thyroid cancer has been relatively underfunded compared to other solid tumors. ITOG and its members have played a critical role in organizing the most sophisticated clinical trials to discover and characterize new drugs for thyroid cancer treatment. Your support will make a difference. Philanthropy is a key for ITOG to achieve success. Hundreds of individuals whose lives have been touched by thyroid cancer have contributed to our mission. Make your voice heard by donating today.

ITOG is a 501(c)(3) tax-exempt public charity. Donations are tax deductible.

GET Involved

Submit an Item to the ITOG Monthly Update - March 2019 Edition

All submissions must be relevant to the mission and Purpose of ITOG. Please take time to proof and edit submissions. Requesting Member submissions no later than February 28, 2019

Submission Guidelines:
- No more than 150 words
- Include the name of author, job title, email and institution
- All submissions should be saved in MS Word
- Photos and artwork send as .jpg files.
- Recent publications
- Upcoming & recently completed
OUR MISSION

The mission of the International Thyroid Oncology Group is to catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.

Our members have led paradigm changing clinical trials for thyroid cancer patients. These trials have already resulted in the FDA approval of two new drugs for medullary thyroid cancer, and innovative new approaches for treating differentiated thyroid cancer. We are doctors, scientists, and patients whose lives and careers are focused on identifying new therapies for thyroid cancer.

ITOG is building on the success of our members by forging collaborative efforts that can accelerate drug discovery and clinical trials. These efforts require your involvement. You can help us catalyze a cure by making a financial contribution to ITOG, a 501(c)(3) tax-exempt public charity; your contribution may be tax deductible.

Copyright © *|2018* *International Thyroid Oncology Group (ITOG)|*, All rights reserved.